DRG Market Assessment reports

Chronic Hepatitis C (HCV) affects several thousand people in Brazil and Colombia. New therapies allow cure in a short period of time with minimal side effects, in contrast to older options. Brazil…

Glomerulonephritis (GN) is a condition involving inflammation of the glomerulus, which plays an important role in the filtration of blood into the kidney. If the glomerulus becomes inflamed and…

The term dyslipidemia refers to abnormalities in the composition, concentration, or size of lipoproteins in the circulation. Dyslipidemia is a key modifiable risk factor for cardiovascular (CV)…

The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are…

Unipolar depression—comprising major depressive disorder (MDD), minor depression, and dysthymia—is a highly prevalent psychiatric disorder affecting nearly 81 million individuals in the seven…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor-alpha (TNF-alpha) inhibitors and interleukin-12 and…

Multiple label expansions of premium-priced agents and the launch of seven novel therapies will fuel the significant growth of the NHL market over the ten-year forecast period. The biosimilar…

A number of filgrastim and epoetin alfa biosimilars are available to European oncologists, and since 2015, U.S. oncologists have had access to Zarxio—the first biosimilar launched in the United…

Neuropathic pain can develop after nerve lesions form at any level of the somatosensory nervous system, peripheral or central; the precise mechanisms that generate pain post-nerve injury are not…

Breast cancer requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, chemotherapies, and targeted therapies. Treatment decisions are influenced by disease stage,…

The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded and competitive following…

Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions…